Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial

Abstract

These results confirm the efficacy and safety of GemOx, but this study failed to demonstrate a statistically significant advantage in terms of OS compared with Gem. Because GemOx is the first combined treatment to be superior to Gem alone in terms of clinical benefit, this promising regimen deserves further development.

Prognostic value of lymph node metastases detected during surgical exploration for pancreatic or periampullary cancer: A systematic review and meta-analysis

“…5 Survival of patients with locally advanced pancreatic cancer is around 10 months. 3,4,32 The pooled data demonstrate that patients with (pancreatic) cancer and hepatic-artery LNM had an estimated pooled mean survival of 15 months. Estimated pooled mean survival following pancreatoduodenectomy with para-aortic LNM was 13 months.…”

“…1,2 In pancreatic cancer, forty percent of patients present with locally advanced disease, with an overall survival following palliative chemotherapy of 10 months. 3,4 In those patients with metastatic disease survival (7 months) is even shorter. 5 Surgery is feasible in 20% of patients, and following adjuvant chemotherapy may achieve a 5-year survival rate of 20%.…”

Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer

“…Chemotherapy as a sole modality improves survival in patients with locally advanced or metastatic disease (Palmer et al, 1994;Glimelius et al, 1996); however, even with the current regimens, median overall survival has ranged from 3.3 to 11.5 months in phase II trials and has generally been not more than 7 months in phase III trials (Burris et al, 1997;Berlin et al, 2002;Colucci et al, 2002;Maisey et al, 2002;Moore et al, 2003;Petty et al, 2003;Rocha Lima et al, 2004;Lopes and Rocha Lima, 2005;Louvet et al, 2005;Oettle et al, 2005). There is little published information on the effectiveness of chemotherapy alone in preventing local failure, but an apparent improvement in survival has been reported in two recent large phase III studies, which had a significant subset of patients with locally advanced disease Poplin et al, 2006a).…”

A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas

“…Gemcitabine, a nucleoside analog that inhibits DNA synthesis by blocking DNA polymerase and the M1 binding site of ribonucleotide reductase (RR), is standard of care for advanced pancreatic cancer [2]. Phase III trials of 5-FU, CPT-11, cisplatin, or oxaliplatin with gemcitabine did not improve overall survival (OS) compared to single-agent gemcitabine [3][4][5][6][7]. Although OS improved when combining gemcitabine with erlotinib (6.24 vs. 5.91 months) [8], this gain was minimal and underscores the need for novel treatments for pancreatic cancer.…”